TScan Therapeutics financials
$0.3175−6.62%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $982.0K | $2.6M | $2.5M | $3.1M | $2.2M | $665.0K | $1.0M | $536.0K | $566.0K | $7.2M | $3.9M |
| Gross profit | $1.1M | $982.0K | $2.6M | $2.5M | $3.1M | $2.2M | $665.0K | $1.0M | $536.0K | $566.0K | $7.2M | $3.9M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$30.5M | -$29.1M | -$23.9M | -$37.1M | -$38.7M | -$36.3M | -$36.7M | -$32.6M | -$34.1M | -$31.4M | -$21.4M | -$24.7M |
| Net income | -$30.4M | -$28.7M | -$23.0M | -$35.7M | -$37.0M | -$34.1M | -$35.8M | -$29.9M | -$31.7M | -$30.1M | -$19.6M | -$23.0M |
| Net margin | −2888.6% | −2919.1% | −895.1% | −1422.1% | −1201.3% | −1571.9% | −5384.8% | −2849.1% | −5906.9% | −5325.4% | −272.0% | −591.6% |
| Diluted EPS | $-0.23 | $-0.22 | $-0.18 | $-0.28 | $-0.28 | $-0.26 | $-0.30 | $-0.25 | $-0.28 | $-0.32 | $-0.20 | $-0.24 |
| EBITDA | -$29.8M | -$28.4M | -$23.1M | -$36.3M | -$38.0M | -$35.6M | -$36.0M | -$31.6M | -$33.0M | -$30.1M | -$20.1M | -$23.5M |
| Operating cash flow | -$27.5M | -$24.3M | -$31.6M | -$32.9M | -$33.3M | -$37.6M | -$27.4M | -$27.9M | -$26.2M | -$29.3M | -$23.8M | $8.0M |
| Free cash flow | -$28.0M | -$24.3M | -$31.8M | -$34.3M | -$34.5M | -$39.1M | -$28.3M | -$29.3M | -$27.1M | -$30.0M | -$24.2M | $6.6M |
| Diluted shares | 129.9M | 129.9M | 129.9M | 129.8M | 129.7M | 129.7M | 121.0M | 118.7M | 113.4M | 94.9M | 96.1M | 94.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $100.2M | $128.1M | $152.4M | $169.5M | $169.4M | $154.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $14.9M | $48.7M | $97.6M |
| Total debt | $32.8M | $32.7M | $32.5M | $32.4M | $32.3M | $32.2M |
| Total assets | $171.5M | $202.0M | $228.8M | $262.2M | $298.6M | $332.7M |
| Total liabilities | $102.4M | $105.1M | $105.7M | $118.2M | $121.8M | $122.5M |
| Shareholders' equity | $69.0M | $96.9M | $123.1M | $144.0M | $176.7M | $210.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology